FDA Panel Recommends Approval for Novartis CAR-T Cell Therapy – Drug Discovery & Development
Drug Discovery & Development |
FDA Panel Recommends Approval for Novartis CAR–T Cell Therapy
Drug Discovery & Development The U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee unanimously voted to recommend approval for CTL019, an experimental cancer drug that belongs to a class of drugs called CAR T-cell therapies, which is a form of … FDA Panel Unanimously Recommends Approval for Novartis' CAR T-Cell Therapy CTL019 CAR–T gene therapy for leukemia clears FDA hurdle Novartis' stellar CAR–T efficacy data steamrolls safety doubts to power landmark cancer therapy toward approval |
